Sign Up for Our E-Newsletter

Statement from Colon Cancer Alliance CEO Michael Sapienza on AHCA assessment by the CBO

Posted on May 24, 2017

Today the Congressional Budget Office (CBO) provided an assessment of what will happen if the American Health Care Act (AHCA) becomes law. The synopsis provides negative foreshadowing, especially in the cancer community, with statistics including: 51 million Americans will be uninsured by 2026, a dramatic increase in out-of-pocket healthcare costs, and a steep decrease in access to life-saving treatments and care. Read more

UPDATED as of 5/24/17: Keytruda Approved for MSI-H Colorectal Cancer Patients

Posted on May 23, 2017

Merck’s Keytruda has just been approved by the FDA for patients with a microsatellite instability-high (also known as MSI-H) or a mismatch repair deficient (dMMR) biomarker following progression on a fluoropyrimidine, oxaliplatin, and irinotecan. This marks an unprecedented step for the FDA, as it is the first time they have approved a cancer drug based on genetics rather than tumor location.

The FDA approval of Merck’s Keytruda is a game changer for both our colorectal cancer community as well as the cancer community at-large,” said Michael Sapienza, Colon Cancer Alliance CEO. “While the results from Keytruda’s recent clinical trial are incredibly promising, the biggest victory here is that this approval sets a precedent for expedited approval for other new drugs across the genetic spectrum. For every cancer patient, time is of the utmost importance. In the future, colorectal cancer patients could get faster access to treatments working for breast or lung cancer.”

Read more

Age 39 + Trying Keytruda, the Newest FDA-Approved Drug

Posted on May 22, 2017

Aliscia Krecisz was only 39 when she was diagnosed. For years she was told her symptoms were only a result of her colitis and she was too young for colorectal cancer, only to find out she had advanced stage disease. Thanks to her doctor and the Colon Cancer Alliance, she was able to get her tumor tested and, because of her genetic status as MSI-H, she was enrolled into an immunotherapy treatment and has been responding well. Since being diagnosed, she has become passionate about advocating for those diagnosed under 50 as well as the importance of getting second (or third or fourth!) opinions.  Read more

In Memoriam: Remembering Pam W.

Posted on May 17, 2017

Our friend and volunteer Pam Weyant died on April 14th after living with active disease for 7 ½ years.

Pam was loving and real. She was a wonderful mother to her two boys whom she loved more than anything. She was so very proud of all they had accomplished. While spending time with Pam I came to realize many called her Mama Weyant, she took care of everyone around her. She was school librarian for 30+ years and a supporter of students and teachers. Read more

5 Tips for Cancer Patients if You Struggle with Survivor Guilt

Posted on May 16, 2017

Recently, we asked our Facebook community if they’ve experienced what’s known as “survivor guilt” and how they cope with the myriad of challenges beyond the physical that come with having cancer.

Survivor’s guilt can range from questions of “Why me?” and “Why did I survive?” to depression and even suicidal thoughts. Some may try to make sense of why they survived and others didn’t, while some people may feel guilty about the changes their families are going through. In its more extreme forms, survivor’s guilt is called Post Traumatic Stress Disorder (PTSD). Read more